Peter Trask

TL;DR: Compared with TCH+P, T-DM1+P resulted in a higher risk of a EFS event owing to locoregional progression events before surgery, a similar risk of an IDFS event, fewer grade 3 or greater AEs during neoadjuvant treatment, and more AEs leading to treatment discontinuation during adjuvant treatment.

TL;DR: Most previously untreated patients with CD20+ DLBCL or FL preferred s.c. to i.v. rituximab administration and patient satisfaction with ritUXimab treatment was generally greater with s.C. versus i.V. administration.

TL;DR: LIFA Q3W was well tolerated and improved objective response rate with a modest, nonstatistically significant improvement of PFS compared with PLD in platinum-resistant OC, thereby highlighting the importance of evaluating both response rates and duration of response when evaluating ADCs in OC.

TL;DR: In HAVEN 1 (NCT02622321), there was a statistically significant reduction in bleeding with emicizumab prophylaxis versus no proplylaxis.

TL;DR: The estimand framework will become a key common framework for developing clinical trial objectives for evaluating effects of treatment and will help to ensure that clinical trials used for registration are designed and analysed appropriately, enabling all stakeholders to accurately interpret conclusions about the treatment effects for patient-focused outcomes.